Mike Nally, CEO of Generate Biomedicines, and Jason Silvers, its CFO, discuss the revolutionary impact of AI on protein therapeutics. They delve into how their 'self-driving lab' utilizes machine learning and cryo-electron microscopy to expedite drug discovery, potentially reducing development time and costs significantly. The conversation highlights their data-first approach to overcoming traditional trial-and-error in drug development, unlocking treatments for previously undruggable diseases, and transforming the economics of biotech.
